Objective: To determine the cost-effectiveness of routine administration, irrespective of blood pressure (BP), of a fixed-dose combination of perindopril and indapamide to patients with type 2 diabetes mellitus.
Design, setting and participants: Prospective cost-effectiveness analysis within the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial, an international, multicentre, randomised controlled trial of 11 140 participants with type 2 diabetes randomly allocated to receive perindopril plus indapamide (4 mg–1.25 mg/day) or placebo.
Main outcome measures: Health-related quality-of-life measured by the EuroQol-5D, resource utilisation, and cost-effectiveness (cost per death averted at 4.3 years’ average follow-up, and estimated cost per life-year gained, by extrapolation).
Results: The mean health-related quality-of-life score of survivors was 0.80 (on a 0–1 scale [death to full health]), with no difference between treatment groups. Active treatment reduced hospital admissions for coronary heart disease and coronary revascularisation by 5%. For the Australian participants, perindopril–indapamide cost A$1368 per patient during the trial period, but reduced total hospitalisation costs by A$410 and other medication costs (mainly other BP-lowering drugs) by A$332. The absolute reduction in all-cause mortality for the active treatment group was 1.1%, giving a cost per life saved of A$49 200. Lifetime extrapolation gave an estimated cost per life-year saved of A$10 040 (discounted at 5% per year).
Conclusion: The combination of perindopril and indapamide in patients with type 2 diabetes appears to be cost-effective.
Trial registration: United States National Library of Medicine NCT00145925.
- 1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
- 2. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958.
- 3. Gu D, Reynolds K, Wu X, et al; InterASIA Collaborative Group. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension 2002; 40: 920-927.
- 4. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75.
- 5. Patel R, Lawlor DA, Whincup P, et al. The detection, treatment and control of high blood pressure in older British adults: cross-sectional findings from the British Women’s Heart and Health Study and the British Regional Heart Study. J Hum Hypertens 2006; 20: 733-741.
- 6. Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ 2000; 320: 680-685.
- 7. Asia Pacific Cohort Studies Collaboration, Kengne AP, Patel A, Barzi F, et al. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 2007; 25: 1205-1213.
- 8. Patel A, MacMahon S, Chalmers J, et al: ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
- 9. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation. J Hypertens Suppl 2001; 19: S21-28.
- 10. Study rationale and design of ADVANCE: action in diabetes and vascular disease — preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118-1120.
- 11. Gudex C, Kind P. The QALY toolkit. (Discussion paper 38.) York: University of York, Centre for Health Economics, 1988.
- 12. Ware JE, Kosinski M, Dewey J. How to score version two of the SF-36 health survey. Lincoln, RI: QualityMetric Incorporated, 2000.
- 13. Glasziou P, Alexander J, Beller E, Clarke P. Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes 2007; 5: 21.
- 14. Department of Health and Ageing. National Hospital Cost Data Collection (NHCDC) reports. 2007. Round 11 cost weights, peer group report and hospital reference manual for 2006-07. Canberra: DoHA, 2008. http://www.health.gov.au/internet/main/publishing.nsf/Content/health-casemix-data-collections-NHCDCReports (accessed Dec 2007).
- 15. Dolan P, Roberts J. Modelling valuations for Eq-5d health states: an alternative model using differences in valuations. Med Care 2002; 40: 442-446.
- 16. Clarke PM, Glasziou P, Patel A, et al. Event rates, hospital utilization and costs associated with major complications of diabetes: multi-country comparative analysis. PLoS Med 2010; 7: e1000236. doi: 10.1371/journal.pmed.100 0236.
- 17. Raikou M, Gray A, Briggs A, et al; UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317: 720-726.
- 18. Briggs A, Mihaylova B, Sculpher M, et al; EUROPA Trial investigators. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart 2007; 93: 1081-1086.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.